Sikarin PCL

Sikarin maintains a strong capital structure with a debt-to-equity ratio of 0.08, indicating a conservative leverage position relative to the industry median of 0.15. The company's liquidity is assessed as medium, with a current ratio of 3.44, which is above the industry median of 2.8. However, the firm's cash and equivalents of 50 million THB are significantly lower than its long-term debt of 609 million THB, resulting in a net cash deficit. Profitability metrics show a return on equity (ROE) of 9.62% and a return on assets (ROA) of 7.87%, both exceeding the industry medians of 7.2% and 5.8%, respectively. The company's gross margin of 30.1% is in line with the industry median of 30.5%, but its operating margin of 16.2% is slightly below the median of 17.3%, suggesting potential inefficiencies in cost management. Geographically, Sikarin's revenue is heavily concentrated in Thailand, with no disclosed international operations. The company operates in a single business segment focused on pharmaceuticals, with no material diversification across product lines or geographic regions. Looking ahead, Sikarin is projected to grow revenue by 4.2% in the current fiscal year and 3.8% in the next, driven by expansion in its generic drug portfolio and increased market penetration. However, the company's capital expenditure of -379 million THB indicates a reduction in investment, which may limit long-term growth potential. The company faces moderate risk from liquidity constraints, as its cash reserves are insufficient to cover long-term obligations. While dilution risk is currently low, the firm's net cash deficit and potential need for external financing could increase dilution pressure in the future. No recent dilutive events have been disclosed, and the company has not issued new shares in the past 12 months. No recent material events, such as regulatory actions, earnings calls, or major business developments, have been disclosed in the latest filings or transcripts. The company's ESG score of 49.04 and a governance score of 32.77 suggest room for improvement in corporate governance practices.